Neurorentec, a pioneering drug discovery startup spun out of IST Austria and focused on epilepsy and related genetic neurodevelopmental disorders (NDDs), today announced its commitment to turn scientific advances into treatment realities for patients with rare diseases. announced a technology access partnership with Caels Biosciences, a biotechnology company working on Genetic syndromes of neurodevelopment.
The agreement will give Caels Biosciences access to Neurorentech’s NDD drug discovery platform and leverage proprietary cell models and functional screening assays to drive advances in neurodevelopmental disorders research.
Neurolentech’s platform built for NDD drug discovery consists of a vast collection of human-derived neuronal cell lines derived from patients with monogenic and complex neurodevelopmental disorders. With this platform, Caels Biosciences will be able to model the complex neural networks that underlie the clinical features of genetic NDDs at the cellular level and explore the preclinical therapeutic potential of its small molecule pipeline for numerous genetic syndromes. You will be able to investigate.
This collaboration marks an important milestone in Neurorentech’s mission to advance NDD drug discovery and further strengthens the NDD drug discovery platform as a valuable resource for both researchers and industry partners.
“We are excited to collaborate with Caels Biosciences to advance their programs in the field of neurodevelopmental disorders. The unique capabilities of our platform provide unparalleled insight into disease mechanisms. and accelerate the development of new treatments.”
Fiona Nielsen, CEO of Neurorentech
“Our partnership with Neurorentech highlights Caels’ commitment to leveraging cutting-edge technology and innovative platform approaches to accelerate the discovery of treatments for patients with genetic disorders of neurodevelopment. .”
Robert Ring, CEO of Caels Biosciences
